Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:21:58 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:DBVT - DBV TECHNOLOGIES SPON ADS EACH REPR 5 ORD SHS (R/S) - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DBVT - Q0.215.30·23.003.021.26-0.20-0.9352.17,2022,18221.22  21.61  20.250426.185  3.8216:00:14Feb 0515 min RT 2¢

Recent Trades - Last 10 of 2182
Time ETExPriceChangeVolume
16:00:14Q21.26-0.201
16:00:14Q21.26-0.201
16:00:01Q21.26-0.2080
16:00:01Q21.26-0.2080
16:00:01Q21.26-0.20106
16:00:01Q21.26-0.2091
16:00:01Q21.26-0.2029
16:00:01Q21.26-0.20134
16:00:01Q21.26-0.20164
16:00:01Q21.26-0.20156

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 16:30U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
2026-01-16 18:11U:DBVTNews ReleaseDBV Technologies Announces euros166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
2026-01-12 16:00U:DBVTNews ReleaseInformation Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
2026-01-07 16:00U:DBVTNews ReleaseHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
2026-01-05 16:00U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
2025-12-16 16:05U:DBVTNews ReleaseDBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN(TM) Peanut Patch in Peanut Allergic Children Aged 4-7 Years
2025-12-02 16:00U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
2025-11-11 23:50U:DBVTNews ReleaseDBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN(TM) Peanut Patch in Peanut Allergic Children Aged 4-7 Years
2025-11-04 16:30U:DBVTNews ReleaseDBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-11-03 16:30U:DBVTNews ReleaseDBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
2025-11-03 16:25U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
2025-10-30 16:30U:DBVTNews ReleaseDBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
2025-10-30 03:00U:DBVTNews ReleaseDBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
2025-10-29 18:47U:DBVTNews ReleaseDBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
2025-10-28 16:25U:DBVTNews ReleaseDBV Technologies Reports Third Quarter 2025 Financial Results
2025-10-06 17:02U:DBVTNews ReleaseDBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
2025-09-18 16:30U:DBVTNews ReleaseDBV Technologies Announces Resignation of Board Member
2025-09-05 16:30U:DBVTNews ReleaseDBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
2025-09-03 16:30U:DBVTNews ReleaseDBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-01 16:05U:DBVTNews ReleaseInformation regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025